COGNITION THERAPEUTICS INC
CGTX · XNASCIK 1455365fmd_12DQTWQ06533FN9YQ552BNQTYQManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net interest income | (2) | (1) | (0) | (0) | – | – |
| Research and development | 13 | 19 | 30 | 37 | 42 | 37 |
| Total operating expenses | 17 | 29 | 44 | 51 | 54 | 48 |
| Operating income | (17) | (29) | (44) | (51) | (54) | (48) |
| Interest expense | 2 | 1 | – | – | – | – |
| Other non-operating income (expense) | 10 | 17 | 22 | 25 | 20 | 24 |
| Income before taxes | (8) | (12) | (21) | (26) | – | – |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (12) | (21) | (26) | – | – |
| Net income | (8) | (12) | (21) | (26) | (34) | (23) |
| Net income to common shareholders | (12) | (16) | (21) | – | – | – |